BACKGROUND: White cell (WBC)-reduced platelet concentrates (PCs) are d
efined by their absolute WBC count, a criterion which provides no info
rmation regarding the various WBC subsets contained in the PC. These h
eterogeneous cells are known to mediate different physiologic and path
ophysiologic functions and account for distinct adverse transfusion re
sponses.This study describes a method which allows the detection and q
uantification of these subsets and characterizes their presence in a v
ariety of platelet components. STUDY DESIGN AND METHODS: Random-donor
pooled PCs (RD PCs) and single-donor apheresis PCs (SD PCs) were studi
ed. RD PCs consisting of 6 units of 2- to 3-day old PCs were randomly
assigned to be filtered with one of four WBC-reduction filters from th
ree different manufacturers (n = 34). The residual WBCs were pelleted
by centrifugation and isolated on a density gradient. The various WBC
subsets were quantified by flow cytometry in unfiltered and filtered P
Cs using fluorescence and two-angle light scatter. SD PCs obtained wit
h two manufacturer's systems and three processing protocols (n = 30) w
ere studied in like manner. RESULTS: WBC counts for non-WBC-reduced PC
s averaged 3 x 10(8) in RD PCs and ranged from 8.6 to 9.6 x 10(6) per
SD PC. Residual WBC counts in filtered PCs ranged from 2.3 x 10(4) to
2.2 x 10(5) and those in WBC-reduced SD PCs averaged 2.2 x 105 per uni
t. The data demonstrate significant phenotypic differences among PCs p
roduced with various procedures. All SD PCs and two of four filtered R
D PCs contained five WBC populations including granulocytes and monocy
tes, while RD PCs filtered with the remaining manufacturer's devices c
ontained only lymphocytes. CONCLUSION: The data confirm that distinct
phenotypic differences exist among PCs prepared with differ ent device
s and/or procedures. It is suggested that as for non-generic pharmaceu
ticals, the clinical benefits of these various PCs should be individua
lly proved.